LV12558A - Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate - Google Patents

Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate

Info

Publication number
LV12558A
LV12558A LV000092A LV000092A LV12558A LV 12558 A LV12558 A LV 12558A LV 000092 A LV000092 A LV 000092A LV 000092 A LV000092 A LV 000092A LV 12558 A LV12558 A LV 12558A
Authority
LV
Latvia
Prior art keywords
methylphenidate
attention deficit
compositions
treatment
methods
Prior art date
Application number
LV000092A
Other languages
English (en)
Other versions
LV12558B (lv
Inventor
Juan Mantelle
Terese A Dixon
Original Assignee
Noven Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26750154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV12558(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Noven Pharma filed Critical Noven Pharma
Publication of LV12558A publication Critical patent/LV12558A/lv
Publication of LV12558B publication Critical patent/LV12558B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
LVP-00-92A 1997-12-15 2000-07-17 Kompozīcijas un paņēmieni ārīgam metilfenidāta pielietojumam uzmanības trūkuma un uzmanības trūkuma/hiperaktivitātes ārstēšanai LV12558B (lv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6951097P 1997-12-15 1997-12-15
US09/163,351 US6210705B1 (en) 1997-12-15 1998-09-30 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
PCT/US1998/026560 WO1999030694A2 (en) 1997-12-15 1998-12-14 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate

Publications (2)

Publication Number Publication Date
LV12558A true LV12558A (lv) 2000-11-20
LV12558B LV12558B (lv) 2001-03-20

Family

ID=26750154

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-00-92A LV12558B (lv) 1997-12-15 2000-07-17 Kompozīcijas un paņēmieni ārīgam metilfenidāta pielietojumam uzmanības trūkuma un uzmanības trūkuma/hiperaktivitātes ārstēšanai

Country Status (28)

Country Link
US (2) US6210705B1 (lv)
EP (2) EP1037615B1 (lv)
JP (3) JP4316800B2 (lv)
KR (1) KR100633348B1 (lv)
CN (1) CN1368876A (lv)
AR (1) AR014062A1 (lv)
AT (1) ATE260652T1 (lv)
AU (1) AU752027B2 (lv)
BR (1) BR9814282A (lv)
CA (1) CA2315237C (lv)
CZ (2) CZ300535B6 (lv)
DE (1) DE69822199T2 (lv)
DK (1) DK1037615T3 (lv)
ES (2) ES2452517T3 (lv)
HK (2) HK1049447A1 (lv)
HU (1) HU226615B1 (lv)
IL (1) IL136760A0 (lv)
LV (1) LV12558B (lv)
NO (1) NO329974B1 (lv)
NZ (1) NZ505689A (lv)
PE (1) PE20000120A1 (lv)
PL (1) PL195315B1 (lv)
PT (1) PT1037615E (lv)
RU (1) RU2233156C2 (lv)
SI (1) SI20360B (lv)
TR (1) TR200001736T2 (lv)
TW (2) TWI244396B (lv)
WO (1) WO1999030694A2 (lv)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
GB9913458D0 (en) * 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
GB9918735D0 (en) * 1999-08-09 1999-10-13 Straken Limited Transdermal patches
CO5261532A1 (es) * 1999-11-15 2003-03-31 Novartis Ag Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
DE60006284T2 (de) * 1999-12-17 2004-07-29 Celltech Pharma Europe Ltd., Slough Arzneimittel zur behandlung konvulsivischer zustände
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US6905016B2 (en) * 2000-03-14 2005-06-14 Noven Pharmaceuticals, Inc. Packaging system for transdermal drug delivery systems
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
ES2559666T3 (es) * 2001-03-07 2016-02-15 Hisamitsu Pharmaceutical Co., Inc. Parche adhesivo
FR2822049B1 (fr) * 2001-03-13 2003-08-01 Dbv Medica 1 Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation
WO2002074286A1 (en) * 2001-03-16 2002-09-26 Alza Corporation Transdermal patch for administering fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
JP4354678B2 (ja) * 2002-08-28 2009-10-28 久光製薬株式会社 貼付剤
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
CA2810477C (en) 2002-12-13 2013-09-17 Durect Corporation Oral drug delivery system
AU2004285505B2 (en) * 2003-10-28 2010-12-23 Noven Pharmaceuticals, Inc. Transdermal drug delivery device
WO2006078887A2 (en) * 2005-01-20 2006-07-27 Institute For Molecular Medicine, Inc. Methylphenidate derivatives and uses of them
WO2006078984A2 (en) * 2005-01-20 2006-07-27 Institute For Molecular Medicine, Inc. Uses of methylphenidate derivatives
US9393218B2 (en) * 2005-12-23 2016-07-19 Epinamics Gmbh Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers
AU2007221117A1 (en) * 2006-02-27 2007-09-07 Noven Pharmaceuticals, Inc. Transdermal therapeutic system comprising scopolamine
RU2414209C2 (ru) * 2006-05-01 2011-03-20 Колгейт-Палмолив Компани Композиция с силиконовым композитом для ухода за полостью рта
CA2678806C (en) * 2007-02-21 2017-05-16 Connected Health Systems, Llc Treating adhd and other diseases involving inflammation
US20090258061A1 (en) * 2007-10-15 2009-10-15 Johnson & Johnson Once-a-day replacement transdermal administration of fentanyl
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
FR2924350B1 (fr) * 2007-12-03 2010-08-13 Dbv Tech Procede et compositions pour la vaccination par voie cutanee
EP3326621A1 (en) 2007-12-06 2018-05-30 Durect Corporation Oral pharmaceutical dosage forms
RU2505320C2 (ru) * 2007-12-31 2014-01-27 Аккларент, Инк. Повязка для слизистой ткани и способы ее применения
FR2926466B1 (fr) * 2008-01-23 2010-11-12 Dbv Tech Procede de fabrication de patchs par electrospray
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc METHODS AND THERAPEUTIC COMPOUNDS
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
JP5155128B2 (ja) * 2008-12-11 2013-02-27 日東電工株式会社 メチルフェニデート貼付製剤
CA2976789C (en) * 2009-06-05 2019-12-31 Megtec Systems, Inc. Method of drying a web of printed material
EP2364695A1 (en) 2010-02-10 2011-09-14 Nitto Denko Corporation Methylphenidate patch preparation
US20110200663A1 (en) * 2010-02-12 2011-08-18 Nitto Denko Corporation Methylphenidate patch preparation
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
ES2883589T3 (es) 2011-03-23 2021-12-09 Ironshore Pharmaceuticals & Dev Inc Procedimientos y composiciones para el tratamiento del trastorno de déficit de atención
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
BR112014002084B1 (pt) 2011-07-28 2022-03-29 Kempharm, Inc Composição de pró-fármaco e uso de conjugado de metilfenidato
US9717697B2 (en) 2012-10-15 2017-08-01 Noven Pharmaceuticals, Inc. Compositions and methods for the transdermal delivery of methylphenidate
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9314470B2 (en) 2012-12-28 2016-04-19 Noven Pharmaceuticals, Inc. Transdermal drug delivery systems for levonorgestrel and ethinyl estradiol
US9295726B2 (en) 2012-12-28 2016-03-29 Noven Pharamceuticals, Inc. Multi-polymer compositions for transdermal drug delivery
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US11337936B2 (en) 2013-03-14 2022-05-24 Noven Pharmaceuticals, Inc. Amphetamine transdermal compositions with acrylic block copolymer
AR095259A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
AR095260A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones de anfetaminas transdérmicas estables y métodos de fabricación
ES2864669T3 (es) 2013-12-25 2021-10-14 Fujimoto Co Ltd Agente profiláctico y terapéutico para el trastorno por déficit de atención/hiperactividad
US9980921B2 (en) * 2016-06-30 2018-05-29 Taho Pharmaceuticals Ltd. Transdermal delivery system containing methylphenidate or its salts and methods thereof
CN106511264A (zh) * 2016-11-15 2017-03-22 北京万全德众医药生物技术有限公司 一种盐酸哌甲酯口服溶液剂及其制备方法
CA3046486A1 (en) 2016-12-11 2018-06-14 Kempharm, Inc. Compositions comprising methylphenidate-prodrugs, processes of making and using the same
EP3598982A1 (en) 2018-07-23 2020-01-29 Centre National De La Recherche Scientifique Bioconjugates of neuropeptides derivatives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957880A (en) 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US4310509A (en) 1979-07-31 1982-01-12 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
JP2693212B2 (ja) * 1989-03-28 1997-12-24 日東電工株式会社 疾患治療用テープ製剤
AU1992592A (en) * 1991-05-24 1993-01-08 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
US5629019A (en) 1992-02-27 1997-05-13 Alza Corporation Formulations with hydrophobic permeation enhancers
AU4673993A (en) 1992-07-28 1994-02-14 Procter & Gamble Company, The Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether
CH691209A5 (de) 1993-09-06 2001-05-15 Scherrer Inst Paul Herstellungsverfahren für einen Polmerelektrolyten und elektrochemische Zelle mit diesem Polymerelektrolyten.
EP0689920B1 (de) 1994-06-29 1999-10-13 Hennecke GmbH Verfahren und Vorrichtung zum kontinuierlichen Herstellen von Schaumstoffblöcken oder Schaumstoffbahnen
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
WO1998039042A1 (en) 1997-03-07 1998-09-11 Jackson Richard R Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
GB9711032D0 (en) 1997-05-30 1997-07-23 Johnson Matthey Plc Compound as a stimulant for the central nervous system
WO2001044720A1 (fr) 1999-12-15 2001-06-21 Osaka Gas Co., Ltd. Distributeur de fluide, dispositif a bruleur, moteur de turbine a gaz, et systeme cogenerateur

Also Published As

Publication number Publication date
HUP0004539A3 (en) 2006-06-28
PT1037615E (pt) 2004-07-30
CZ305817B6 (cs) 2016-03-23
HK1049447A1 (zh) 2003-05-16
ES2452517T3 (es) 2014-04-01
PL341596A1 (en) 2001-04-23
NZ505689A (en) 2003-01-31
CZ20002209A3 (cs) 2000-11-15
EP1037615B1 (en) 2004-03-03
EP2314288B1 (en) 2013-12-11
ATE260652T1 (de) 2004-03-15
AU752027B2 (en) 2002-09-05
CZ2009132A3 (cs) 2016-03-23
CA2315237A1 (en) 1999-06-24
NO20003096D0 (no) 2000-06-15
CN1368876A (zh) 2002-09-11
EP1037615A2 (en) 2000-09-27
HK1156872A1 (en) 2012-06-22
US6348211B1 (en) 2002-02-19
AR014062A1 (es) 2001-01-31
NO20003096L (no) 2000-08-15
AU1824999A (en) 1999-07-05
TWI244396B (en) 2005-12-01
JP4316800B2 (ja) 2009-08-19
IL136760A0 (en) 2001-06-14
EP2314288A1 (en) 2011-04-27
DE69822199T2 (de) 2005-02-17
US6210705B1 (en) 2001-04-03
LV12558B (lv) 2001-03-20
RU2233156C2 (ru) 2004-07-27
CZ300535B6 (cs) 2009-06-10
CA2315237C (en) 2009-12-01
BR9814282A (pt) 2000-10-03
HUP0004539A2 (hu) 2001-06-28
PE20000120A1 (es) 2000-02-19
DE69822199D1 (de) 2004-04-08
WO1999030694A2 (en) 1999-06-24
JP2013056944A (ja) 2013-03-28
JP2009073856A (ja) 2009-04-09
TR200001736T2 (tr) 2001-01-22
TW200406231A (en) 2004-05-01
HU226615B1 (en) 2009-04-28
SI20360B (sl) 2008-06-30
DK1037615T3 (da) 2004-07-12
KR20010033114A (ko) 2001-04-25
PL195315B1 (pl) 2007-08-31
ES2219926T3 (es) 2004-12-01
KR100633348B1 (ko) 2006-10-16
NO329974B1 (no) 2011-01-31
SI20360A (sl) 2001-04-30
JP2002510600A (ja) 2002-04-09
WO1999030694A3 (en) 1999-08-19
TWI242452B (en) 2005-11-01

Similar Documents

Publication Publication Date Title
LV12558A (lv) Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
DK1039874T3 (da) Sammensætninger og metoder til behandling af alopecia
DE69823852D1 (de) Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
ATE207759T1 (de) Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels
UA32429C2 (uk) Засіб для лікування нетримання сечі
DE69736183D1 (de) Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen
ATE342278T1 (de) Verfahren zur behandlung von diabetes mittels kgf
DE69403969D1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
BR9710250A (pt) Composto composição farmacêutica e processos para tratar uma infecção bacteriana em um paciente em necessidade de tal tratamento e para produzir um composto de bromotiacumicina
ATA901396A (de) Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE249832T1 (de) Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation
PT1063978E (pt) Metodo de tratamento de dor de neuroma
NO20034453L (no) Anvendelse av CD25-bindende molekyler i steroid-resistente pasienter
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
CO4970785A1 (es) Composiciones y metodos para tratar con metilfenidato el deficit de la atencion y el deficit de la atencion con hiperactividad
NO960866L (no) Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler
NO20014180L (no) Anvendelse av fluorinerte triazoler til behandling av smerte og smertefulle lidelser eller oppmerksomhetshunger
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
UA29709A (uk) Спосіб лікування захворювань гастродуоденальної системи та суміш для його здійснення
ATE184487T1 (de) Transdermales therapeutisches system für silatranverbindungen
UA36490A (uk) Спосіб лікування гнійно-септичних захворювань м'яких тканин
UA36485A (uk) Спосіб лікування генералізованого пародонтиту